Categories Earnings, LATEST, Technology
Smart Global stock gets slammed on Q4 earnings and sales miss; provides dismal outlook
Shares of Smart Global Holdings (NASDAQ: SGH) plunged about 15% after the company missed earnings and sales estimates for the fourth quarter of 2019 and weaker-than-expected outlook for 1Q20. Smart Global reported adjusted earnings of $0.50 per share on sales of $278.4 million. Analysts had expected specialty memory company to post earnings of $0.67 per share on sales of $285.04 million for Q4 2019.
SGH stock, which ended up 2.13% at $25.41 today, was trading down about 17% in the extended trading hours. On a GAAP basis, the company reported earnings of $0.24 per share compared with earnings of $1.28 per share in the prior-year quarter. Weakness in the supply chain services business resulted in lower-than-projected fourth quarter 2019 results.
When reporting the third quarter 2019 results, the Newark, California-based firm had projected Q4 2019 adjusted earnings to come in the range of $0.55 and $0.65 per share and GAAP EPS in the range of $0.33 to $0.43. Sales for the fourth quarter ending August 30, 2019, was eyed in the range of $270 million to $280 million.
Commenting on the fiscal 2019 results, CEO Ajay Shah said, “In the second half of fiscal 2019 component pricing in the memory market declined significantly, which primarily impacted our business in Brazil and, to a lesser extent, our Specialty Memory Products, and resulted in overall revenues in fiscal 2019 declining year-over-year by 6%.”
For the first quarter of fiscal 2020 ending November 2, 2019, Smart Global projected adjusted earnings to be between $0.65 and $0.78 per share and GAAP EPS of $0.30 to $0.40. Sales for the first quarter is touted to be between $275 million and $285 million.
Shares of Smart Global have declined 14% so far in 2019 and 12% in the past 52 weeks.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on